Summary & Overview
HCPCS C9024: Liposomal Daunorubicin and Cytarabine Injection
HCPCS Level II code C9024 identifies a liposomal combination injection of daunorubicin and cytarabine (1 mg and 2.27 mg respectively) used for chemotherapy infusions. Nationally, unique HCPCS codes for combination oncology formulations matter for billing clarity, reimbursement consistency, and accurate utilization tracking across hospital outpatient departments and infusion centers.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, how the code is used in clinical infusion workflows, and context on billing practices for liposomal cytotoxic agents. The publication summarizes benchmark payment patterns, common procedural and billing considerations, and policy updates that affect administration and reimbursement of proprietary combination oncology injections.
This report provides clinicians, billing professionals, and policy analysts with concise information on clinical context, typical sites of service, and the administrative implications of using HCPCS Level II code C9024. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9024 describes an injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine. This entry represents a ready-for-use liposomal formulation combining daunorubicin and cytarabine for intravenous administration.
-
Service type: Chemotherapy infusion
-
Typical site of service: Hospital outpatient department or infusion center
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed acute myeloid leukemia (AML) presenting with pancytopenia and confirmed bone marrow blasts is scheduled to receive induction chemotherapy with the liposomal combination of daunorubicin and cytarabine (dosage unit per C9024: 1 mg daunorubicin and 2.27 mg cytarabine per billing unit). The clinical workflow includes outpatient or inpatient chemotherapy ordering by a hematology-oncology physician, pharmacy compounding of the liposomal formulation, verification of dose based on body surface area, pre-infusion nursing assessment including baseline labs (CBC with differential, comprehensive metabolic panel), premedication as indicated, infusion administration via peripheral IV or central venous catheter, monitoring for infusion reactions and tumor lysis syndrome, and documentation of chemotherapy administration in the infusion record. Typical sites of service are the hospital inpatient unit or an oncology infusion center depending on disease severity and insurance authorization. Common administrative steps include prior authorization, application of modifier 51 when multiple procedures or drugs are billed on the same date, and linkage to an appropriate AML ICD-10 diagnosis for medical necessity and coverage adjudication.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
51 | Multiple Procedures |